Journal Article Review Epublish
PubMed: 40432089 DOI: 10.3390/vaccines13050477
Herpes Zoster Vaccination: Insights into Efficacy, Safety, and Guidelines.
Vaccines (Basel) 13(5)
Authors: Michał Oleszko, Paweł Zapolnik, Hanna Czajka
Affiliations
- College of Medical Sciences, University of Rzeszów, 35-315 Rzeszów, Poland.
Abstract
BACKGROUND
The varicella-zoster virus (VZV) is a human herpesvirus that primarily causes varicella (chickenpox) as an initial infection, characterized by distinctive skin lesions. It can later reactivate, leading to herpes zoster (shingles). Once reactivated, VZV infection may result in serious complications, the most common being postherpetic neuralgia. Fortunately, vaccination can prevent this condition.
OBJECTIVES
In this study, we provide a comprehensive analysis of zoster vaccines, including clinical trials, safety profiles, and reimbursement guidelines across various countries.
RESULTS
Our findings confirm the vaccine's effectiveness and safety across diverse populations, aligning with previous clinical trials and real-world data, and summarize global vaccination guidelines.
MeSH
Safety, Vaccines, Chickenpox, Vaccination, Herpes Zoster, Viruses, Allergy And Immunology, Communicable Diseases, Infections